{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:42:38Z","timestamp":1789188158216,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,20]],"date-time":"2013-12-20T00:00:00Z","timestamp":1387497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s12035-013-8605-5","type":"journal-article","created":{"date-parts":[[2013,12,20]],"date-time":"2013-12-20T18:10:49Z","timestamp":1387563049000},"page":"159-167","source":"Crossref","is-referenced-by-count":36,"title":["Chaperone Therapy for GM2 Gangliosidosis: Effects of Pyrimethamine on \u03b2-Hexosaminidase Activity in Sandhoff Fibroblasts"],"prefix":"10.1007","volume":"50","author":[{"given":"Elena","family":"Chiricozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Niemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Aureli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Magini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Loberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Prinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Polchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Emiliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Caillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Sonnino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,20]]},"reference":[{"key":"8605_CR1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1042\/bst0280150","volume":"28","author":"B Winchester","year":"2000","unstructured":"Winchester B, Velloidi A, Young E (2000) The molecular basis of lysosomal storage diseases and their treatment. Biochem Soc Trans 28:150\u2013154","journal-title":"Biochem Soc Trans"},{"key":"8605_CR2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrm1423","volume":"5","author":"AH Futerman","year":"2004","unstructured":"Futerman AH, van Meer G (2004) The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 5:554\u2013565","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8605_CR3","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.bbamem.2006.05.027","volume":"1758","author":"T Kolter","year":"2006","unstructured":"Kolter T, Sandhoff K (2006) Sphingolipid metabolism diseases. Biochim Biophys Acta 1758:2057\u20132079","journal-title":"Biochim Biophys Acta"},{"key":"8605_CR4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000112332","volume":"6","author":"E Conzelmann","year":"1983","unstructured":"Conzelmann E, Sandhoff K (1983) Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev Neurosci 6:58\u201371","journal-title":"Dev Neurosci"},{"key":"8605_CR5","first-page":"4","volume":"20","author":"S Sonnino","year":"2012","unstructured":"Sonnino S, Prinetti A (2012) Membrane domains and the \u201clipid raft\u201d concept. Curr Med Chem 20:4\u201321","journal-title":"Curr Med Chem"},{"key":"8605_CR6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Calague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249\u2013254","journal-title":"JAMA"},{"key":"8605_CR7","first-page":"3827","volume-title":"The metabolic and molecular bases of inherited disease","author":"RA Gravel","year":"2001","unstructured":"Gravel RA, Kaback MM, Proia RL, Sandhoff K, Suzuki K, Suzuki K (2001) The GM2 gangliosidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York pp, pp 3827\u20133876","edition":"8"},{"key":"8605_CR8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF00219337","volume":"88","author":"P Leinekugel","year":"1992","unstructured":"Leinekugel P, Michel S, Conzelmann E, Sandhoff K (1992) Quantitative correlation between the residual activity of \u03b2-hexosaminidase A and arysulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 88:513\u2013523","journal-title":"Hum Genet"},{"key":"8605_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrn1725","volume":"6","author":"M Jeyakumar","year":"2005","unstructured":"Jeyakumar M, Dwek RA, Butters TD, Platt FM (2005) Storage solutions: treating lysosomal disorders of the brain. Nat Rev Neurosci 6:1\u201312","journal-title":"Nat Rev Neurosci"},{"key":"8605_CR10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0962-8924(03)00033-3","volume":"13","author":"DJ Sillence","year":"2003","unstructured":"Sillence DJ, Platt FM (2003) Storage disease: new insights into sphingolipid functions. Trends Cell Biol 13:195\u2013203","journal-title":"Trends Cell Biol"},{"key":"8605_CR11","first-page":"3635","volume-title":"The Metabolic and Molecular Bases of Inherited Diseases","author":"GA Grabowski","year":"2001","unstructured":"Grabowski GA, Beutler E (2001) Gaucher disease. In: Scriver C, Beaudet A, Sly W, Valle D (eds) The Metabolic and Molecular Bases of Inherited Diseases, 8th edn. McGraw-Hill, New York pp, pp 3635\u20133668","edition":"8"},{"key":"8605_CR12","unstructured":"Ratko TA, Marbella A, Godfrey S, Aronson N. (2013) Enzyme-Replacement Therapies for Lysosomal Storage Diseases. Technical Brief. No. 12. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-2007-10058-I.) Rockville, MD: Agency for Healthcare Research and Quality. January www.effectivehealthcare.ahrq.gov\/reports\/final.cfm"},{"key":"8605_CR13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1042\/bj1730997","volume":"173","author":"TM Bearpark","year":"1978","unstructured":"Bearpark TM, Stirling JL (1978) A difference in the specificities of human liver N-acetyl-beta-hexosaminidase A and B detected by their activities towards glycosaminoglycan oligosaccharides. Biochem J 173:997\u20131000","journal-title":"Biochem J"},{"key":"8605_CR14","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1021\/bi9524575","volume":"35","author":"EY Hou","year":"1996","unstructured":"Hou EY, Tse R, Mahuran DJ (1996) Direct determination of the substrate specificity of the alpha-active site in heterodimeric beta-hexosaminidase A. Biochemistry 35:3963\u20133969","journal-title":"Biochemistry"},{"key":"8605_CR15","doi-asserted-by":"crossref","first-page":"7568","DOI":"10.1016\/S0021-9258(17)39645-X","volume":"260","author":"HJ Kytzia","year":"1985","unstructured":"Kytzia HJ, Sandhoff K (1985) Evidence for two different active sites on human beta-hexosaminidase A. Interaction of GM2 activator protein with beta-hexosaminidase A. J Biol Chem 260:7568\u20137572","journal-title":"J Biol Chem"},{"key":"8605_CR16","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.bbamem.2006.05.027","volume":"1758","author":"T Kolter","year":"2006","unstructured":"Kolter T, Sandhoff K (2006) Sphingolipid metabolism disease. BBA-Biomembranes 1758:2057\u20132079","journal-title":"BBA-Biomembranes"},{"key":"8605_CR17","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1021\/jm101443u","volume":"54","author":"KS Bateman","year":"2011","unstructured":"Bateman KS, Cherney MM, Mahuran DJ, Tropak M, James NG (2011) Crystal structure of \u03b2-hexosaminidase B in complex with pyrimethamine, a potential pharmacological chaperone. J Med Chem 54:1421\u20131429","journal-title":"J Med Chem"},{"key":"8605_CR18","first-page":"105","volume":"1455","author":"DJ Mahuran","year":"1999","unstructured":"Mahuran DJ (1999) Biochemical consequences of mutations causing the GM2 gangliosidosis. Biochem Biophys Acta 1455:105\u2013138","journal-title":"Biochem Biophys Acta"},{"key":"8605_CR19","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1111\/j.1742-4658.2007.06040.x","volume":"274","author":"MB Tropak","year":"2007","unstructured":"Tropak MB, Mahuran DJ (2007) Lending a helping hand, screening chemical libraries for compounds that enhance \u03b2-hexosaminidase A activity in GM2 gangliosidosis cells. FEBS J 274:4951\u20134961","journal-title":"FEBS J"},{"key":"8605_CR20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/iub.284","volume":"62","author":"M Beck","year":"2010","unstructured":"Beck M (2010) Therapy for lysosomal storage disorders. IUMB Life 62:33\u201340","journal-title":"IUMB Life"},{"key":"8605_CR21","doi-asserted-by":"crossref","first-page":"43R","DOI":"10.1093\/glycob\/cwi076","volume":"15","author":"TD Butters","year":"2005","unstructured":"Butters TD, Dwek BR, Platt FM (2005) Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 15:43R\u201352R","journal-title":"Glycobiology"},{"key":"8605_CR22","first-page":"7","volume":"3","author":"Y Yoshiyuki Suzuki","year":"2009","unstructured":"Yoshiyuki Suzuki Y, Ogawa S, Sakakibara Y (2009) Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. Perspect Med Chem 3:7\u201319","journal-title":"Perspect Med Chem"},{"key":"8605_CR23","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2174\/138955708785132783","volume":"8","author":"P Leandro","year":"2008","unstructured":"Leandro P, Gomes CM (2008) Protein misfolding in conformational disorders: rescue of folding defects and chemical chaperoning. Mini Rev Med Chem 8:901\u2013911","journal-title":"Mini Rev Med Chem"},{"key":"8605_CR24","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.bbapap.2006.08.012","volume":"1764","author":"T Arakawa","year":"2006","unstructured":"Arakawa T, Ejima D, Kita Y, Tsumoto K (2006) Small molecule pharmacological chaperones: from thermodynamic stabilization to pharmacological drugs. Biochim Biophys Acta 1764:1677\u20131687","journal-title":"Biochim Biophys Acta"},{"key":"8605_CR25","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1600-0854.2004.00232.x","volume":"5","author":"A Ulloa-Aguirre","year":"2004","unstructured":"Ulloa-Aguirre A, Janovick JA, Brothers SP, Conn PM (2004) Pharmacological rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic 5:821\u2013837","journal-title":"Traffic"},{"key":"8605_CR26","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/nrg963","volume":"3","author":"R Desnick","year":"2002","unstructured":"Desnick R, Schuchmann EH (2002) Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 3:954\u2013966","journal-title":"Nat Rev Genet"},{"key":"8605_CR27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/B:BOLI.0000031101.12838.c6","volume":"27","author":"RJ Desnick","year":"2004","unstructured":"Desnick RJ (2004) Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 27:385\u2013410","journal-title":"J Inherit Metab Dis"},{"key":"8605_CR28","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1074\/jbc.M609304200","volume":"282","author":"GH Maegawa","year":"2007","unstructured":"Maegawa GH, Tropak M, Buttner J, Stockley T, Kok F, Clarke JT, Mahuran DJ (2007) Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J Biol Chem 282:9150\u20139161","journal-title":"J Biol Chem"},{"key":"8605_CR29","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1016\/j.febslet.2006.08.041","volume":"580","author":"Y Kacher","year":"2006","unstructured":"Kacher Y, Futerman AH (2006) Genetic diseases of sphingolipid metabolism: pathological mechanisms and therapeutic options. Febs Lett 580:5510\u20135517","journal-title":"Febs Lett"},{"key":"8605_CR30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0165-6147(03)00158-5","volume":"24","author":"JQ Fan","year":"2003","unstructured":"Fan JQ (2003) A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 24:355\u2013360","journal-title":"Trends Pharmacol Sci"},{"key":"8605_CR31","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1517\/14728214.10.4.891","volume":"10","author":"GM Pastores","year":"2005","unstructured":"Pastores GM, Barnett NL (2005) Current and emerging therapies for the lysosomal storage disorders. Exp Opin Emerg Drugs 10:891\u2013902","journal-title":"Exp Opin Emerg Drugs"},{"key":"8605_CR32","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","volume":"99","author":"AR Sawkar","year":"2002","unstructured":"Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A 99:15428\u201315433","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8605_CR33","doi-asserted-by":"crossref","first-page":"13478","DOI":"10.1074\/jbc.M308523200","volume":"279","author":"MB Tropak","year":"2004","unstructured":"Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran DJ (2004) Pharmacological enhancement of beta-hexosaminidase activity in fibroblast from adult Tay-Sachs and Sandhoff patients. J Biol Chem 279:13478\u201313487","journal-title":"J Biol Chem"},{"key":"8605_CR34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0387-7604(01)00216-9","volume":"23","author":"L Tominaga","year":"2001","unstructured":"Tominaga L, Ogawa Y, Taniguchi M, Ohno K, Matsuda J, Oshima A, Suzuki Y, Nanba E (2001) Galactonojirimycin derivatives restore mutant human beta-galactosidase activities expressed in fibroblasts from enzyme-deficient knockout mouse. Brain Dev 23:284\u2013287","journal-title":"Brain Dev"},{"key":"8605_CR35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","volume":"5","author":"JQ Fan","year":"1999","unstructured":"Fan JQ, Ishii S, Asano N, Suzuki Y (1999) Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 5:112\u2013115","journal-title":"Nat Med"},{"key":"8605_CR36","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","volume":"100","author":"J Matsuda","year":"2003","unstructured":"Matsuda J, Suzuki O, Oshima A, Yamamoto Y, Noguchi A, Takimoto K et al (2003) Chemical chaperone therapy for brain pathology in GM1-gangliosidosis. Proc Natl Acad Sci U S A 100:15912\u201315917","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8605_CR37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/infdis\/173.1.91","volume":"173","author":"C Leport","year":"1996","unstructured":"Leport C, Ch\u00eane G, Morlat P, Luft BJ, Rousseau F, Pueyo S, Hafner R, Miro J, Aubertin J, Salamon R, Vild\u00e9 JL (1996) Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. J Infect Dis 173:91\u201397","journal-title":"J Infect Dis"},{"key":"8605_CR38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4269\/ajtmh.1992.46.288","volume":"46","author":"LM Weiss","year":"1992","unstructured":"Weiss LM, Luft BJ, Tanowitz HB, Wittner M (1992) Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis. Am J Trop Med Hyg 46:288\u2013291","journal-title":"Am J Trop Med Hyg"},{"key":"8605_CR39","volume-title":"The Pharmacological Basis of Therapeutics 11th ed","author":"ILO Buxton","year":"2006","unstructured":"Buxton ILO (2006) The Pharmacological Basis of Therapeutics 11th ed. McGraw-Hill Books, New York"},{"key":"8605_CR40","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/infdis\/157.3.580","volume":"157","author":"LM Weiss","year":"1988","unstructured":"Weiss LM, Harris C, Berger M, Tanowitz HB, Wittner M (1988) Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. J Infect Dis 157:580\u2013583","journal-title":"J Infect Dis"},{"key":"8605_CR41","doi-asserted-by":"crossref","first-page":"13046","DOI":"10.1073\/pnas.0501747102","volume":"282","author":"P Kongsaeree","year":"2005","unstructured":"Kongsaeree P, Khongsuk P, Leartsakulpanich U, Chitnumsub P, Tarnchimpoo B, Walkinshaw M, Yuthavong Y (2005) Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci U S A 282:13046\u201313051","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8605_CR42","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/glycob\/cwp183","volume":"20","author":"MB Tropak","year":"2010","unstructured":"Tropak MB, Bukovac SW, Rigat BA, Yonekawa S, Wakarchuk W, Mahuran DJ (2010) A sensitive fluorescence-based assay for monitoring GM2 ganglioside hydrolysis in live patient cells and their lysates. Glycobiology 20:356\u2013365","journal-title":"Glycobiology"},{"key":"8605_CR43","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2010.09.004","volume":"102","author":"JT Clarke","year":"2011","unstructured":"Clarke JT, Mahuran DJ, Sathe S, Kolodny EH, Rigat BA, Raiman JA, Tropak MB (2011) An open-label phase I\/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Mol Genet Metab 102:6\u201312","journal-title":"Mol Genet Metab"},{"key":"8605_CR44","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ymgme.2010.11.163","volume":"102","author":"E Osher","year":"2011","unstructured":"Osher E, Fattal-Valevki A, Sagie L, Urshanski N, Amir-Levi Y, Katzburg S, Peleg L, Lerman-Sagie T, Zimran A, Elstein D, Navon R, Stern N, Valevski A (2011) Pyrimethamine increases \u03b2-hexosaminidase A activity in patients with late onset Tay Sachs. Mol Genet Metab 102:356\u2013363","journal-title":"Mol Genet Metab"},{"key":"8605_CR45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0009-8981(84)90215-8","volume":"143","author":"J Bayleran","year":"1984","unstructured":"Bayleran J, Hechtman P, Saray W (1984) Synthesis of 4-methylumbelliferyl-beta-d-N-acetylglucosamine-6-sulfate and its use in classification of GM2 gangliosidosis genotypes. Clin Chim Acta 143:73\u201389","journal-title":"Clin Chim Acta"},{"key":"8605_CR46","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1172\/JCI114871","volume":"86","author":"K Neote","year":"1990","unstructured":"Neote K, Mcinnes B, Mahuran DJ, Gravel RA (1990) Structure and distribution of an Alu-type deletion mutation in Sandhoff disease. J Clin Invest 86:1524\u20131531","journal-title":"J Clin Invest"},{"key":"8605_CR47","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1371\/journal.pone.0041516","volume":"7","author":"S Zampieri","year":"2012","unstructured":"Zampieri S, Cattarossi S, Oller Ramirez AM, Rosano C, Lourenco CM et al (2012) Sequence and copy number analyses of HEXB gene in patients affected by Sandhoff disease : functional characterization of 9 novel variants. PLoS One 7:415\u2013416","journal-title":"PLoS One"},{"key":"8605_CR48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.nbd.2005.04.017","volume":"20","author":"A Arfi","year":"2005","unstructured":"Arfi A, Bourgoin C, Basso L, Emiliani C, Tancini B, Chigorno V, Li YT, Orlacchio A, Poenaru L, Sonnino S, Caillaud C (2005) Bicistronic lentiviral vector corrects \u03b2-hexosaminidase deficiency in transduced and cross-corrected human Sandhoff fibroblasts. Neurobiol Dis 20:583\u2013593","journal-title":"Neurobiol Dis"},{"key":"8605_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2660(01)44065-X","volume":"44","author":"MM Kaback","year":"2001","unstructured":"Kaback MM, Desnick RJ (2001) Tay-Sachs disease: from clinical description to molecular defect. Adv Genet 44:1\u20139","journal-title":"Adv Genet"},{"key":"8605_CR50","doi-asserted-by":"crossref","first-page":"21705","DOI":"10.1016\/S0021-9258(20)88243-X","volume":"264","author":"CA Brown","year":"1989","unstructured":"Brown CA, Neote K, Leung A, Gravel RA, Mahuran DJ (1989) Introduction of the alpha subunit mutation associated with the B1 variant of Tay-Sachs disease into the beta subunit produces a beta-hexosaminidase B without catalytic activity. J Biol Chem 264:21705\u201321710","journal-title":"J Biol Chem"},{"key":"8605_CR51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/jmg.33.4.341","volume":"33","author":"MG Ribeiro","year":"1996","unstructured":"Ribeiro MG, Sonin T, Pinto RA, Fontes A, Ribeiro H, Pinto E, Palmeira MM, Miranda MC (1996) Clinical, enzymatic, and molecular characterisation of a Portuguese family with a chronic form of GM2-gangliosidosis B1 variant. J Med Genet 33:341\u2013343","journal-title":"J Med Genet"},{"key":"8605_CR52","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/humu.1380010406","volume":"1","author":"EH Mules","year":"1992","unstructured":"Mules EH, Hayflick S, Dowling CE, Kelly TE, Akerman BR, Gravel RA, Thomas GH (1992) Molecular basis of hexosaminidase A deficiency and pseudodeficiency in the Berks County Pennsylvania Dutch. Hum Mutat 1:298\u2013302","journal-title":"Hum Mutat"},{"key":"8605_CR53","doi-asserted-by":"crossref","first-page":"9452","DOI":"10.1016\/S0021-9258(19)38870-2","volume":"265","author":"BH Paw","year":"1990","unstructured":"Paw BH, Moskowitz SM, Uhrhammer N, Wright N, Kaback MM, Neufeld EF (1990) Juvenile GM2 gangliosidosis caused by substitution of histidine for arginine at position 499 or 504 of the alpha-subunit of betahexosaminidase. J Biol Chem 265:9452\u20139457","journal-title":"J Biol Chem"},{"key":"8605_CR54","first-page":"817","volume":"46","author":"R Navon","year":"1990","unstructured":"Navon R, Kolodny EH, Mitsumoto H, Thomas GH, Proia RL (1990) Ashkenazi Jewish and not-Jewish adult GM2 gangliosidosis patients share a common genetic defect. Am J Hum Genet 46:817\u2013821","journal-title":"Am J Hum Genet"},{"key":"8605_CR55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/hmg\/2.1.61","volume":"2","author":"S Akli","year":"1993","unstructured":"Akli S, Chomel JC, Lacorte JM, Bachner L, Poenaru A, Poenaru L (1993) Ten novel mutations in the HEXA gene in non-Jewish Tay-Sachs patients. Hum Mol Genet 2:61\u201367","journal-title":"Hum Mol Genet"},{"key":"8605_CR56","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s10038-003-0082-7","volume":"48","author":"F Matsuzawa","year":"2003","unstructured":"Matsuzawa F, Aikawa S, Sakuraba H, Lan HT, Tanaka A, Ohno K, Sugimoto Y, Ninomiya H, Doi H (2003) Structural basis of the GM2 gangliosidosis B variant. J Hum Genet 48:582\u2013589","journal-title":"J Hum Genet"},{"key":"8605_CR57","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/humu.1380010407","volume":"1","author":"BR Akerman","year":"1992","unstructured":"Akerman BR, Zielenski J, Triggs-Raine BL, Prence EM, Natowicz MR, Lim-Steele JS, Kaback MM, Mules EH, Thomas GH, Clarke JTR, Gravel RA (1992) A mutation common in non-Jewish Tay-Sachs disease: frequency and RNA studies. Hum Muta 1:303\u2013309","journal-title":"Hum Muta"},{"key":"8605_CR58","first-page":"112","volume":"41","author":"H Aryan","year":"2012","unstructured":"Aryan H, Aryani O, Banihashemi K, Zaman T, Houshmand M (2012) Novel mutations in sandhoff disease: a molecular analysis among iranian cohort of infantile patients. Iran J Public Health 41:112\u2013118","journal-title":"Iran J Public Health"},{"key":"8605_CR59","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/ana.10768","volume":"54","author":"SC Blumen","year":"2003","unstructured":"Blumen SC, Bevan S, Abu-Mouch S, Negus D, Kahana M, Inzelberg R, Mazarib A, Mahamid A, Carasso RL, Slor H, Withers D, Nisipeanu P, Navon R, Reid E (2003) A locus for complicated hereditary spastic paraplegia maps to chromosome 1q24-q32. Ann Neurol 54:796\u2013803","journal-title":"Ann Neurol"},{"key":"8605_CR60","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0925-4439(93)90134-M","volume":"1182","author":"PA Bolhuis","year":"1993","unstructured":"Bolhuis PA, Ponne NJ, Bikker H, Baas F, Vianney De Jong JM (1993) Molecular basis of an adult form of Sandhoff disease: substitution of glutamine for arginine at position 505 of the beta-chain of betahexosaminidase results in a labile enzyme. Biochim Biophys Acta 1182:142\u2013146","journal-title":"Biochim Biophys Acta"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-013-8605-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-013-8605-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-013-8605-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:30:39Z","timestamp":1716337839000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-013-8605-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,20]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["8605"],"URL":"https:\/\/doi.org\/10.1007\/s12035-013-8605-5","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,20]]}}}